3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
Radiosurgery
10
Temozolomide
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Trastuzumab
3
Radiation
3
fluciclovine F-18
2
cabazitaxel
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Imaging
2
Erlotinib Hydrochloride
2
Carboplatin
2
Bevacizumab
2
Aminolevulinic Acid
2
tucatinib
1
thymoglobulin
1
tepotinib
1
temsirolimus
1
sodium thiosulfate
1
ribociclib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
neratinib
1
lenvatinib
1
irinotecan sucrosofate
1
gancotamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Brain Neoplasms
×
eribulin
×
Clear all
NCT03637868
2020-05-06
ERIBRAIN
Institut Paoli-Calmettes
Phase 2
Withdrawn